| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,270,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,298 |
221,691 |
456,290 |
785,314 |
| Total Sell Value |
$427,399 |
$3,766,874 |
$7,701,881 |
$12,216,507 |
| Total People Sold |
1 |
2 |
2 |
3 |
| Total Sell Transactions |
10 |
15 |
38 |
53 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Harris Todd |
Chief Executive Officer |
• • – |
2023-03-27 |
4 |
AS |
$16.00 |
$47,408 |
D/D |
(2,963) |
1,701,276 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-27 |
4 |
OE |
$2.25 |
$6,667 |
D/D |
2,963 |
1,704,239 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-24 |
4 |
AS |
$16.00 |
$2,720 |
D/D |
(170) |
1,701,276 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-24 |
4 |
OE |
$2.25 |
$383 |
D/D |
170 |
1,701,446 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-23 |
4 |
AS |
$16.00 |
$77,232 |
D/D |
(4,827) |
527,981 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-23 |
4 |
OE |
$0.61 |
$2,944 |
D/D |
4,827 |
532,808 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-23 |
4 |
AS |
$16.00 |
$44,800 |
D/D |
(2,800) |
1,701,276 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-23 |
4 |
OE |
$2.25 |
$6,300 |
D/D |
2,800 |
1,704,076 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-22 |
4 |
AS |
$16.00 |
$60,800 |
D/D |
(3,800) |
527,981 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-22 |
4 |
OE |
$0.61 |
$2,318 |
D/D |
3,800 |
531,781 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-22 |
4 |
AS |
$16.00 |
$64,688 |
D/D |
(4,043) |
1,701,276 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-22 |
4 |
OE |
$2.25 |
$9,097 |
D/D |
4,043 |
1,705,319 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-21 |
4 |
AS |
$16.00 |
$225,600 |
D/D |
(14,100) |
527,981 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2023-03-21 |
4 |
OE |
$0.61 |
$8,601 |
D/D |
14,100 |
542,081 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-21 |
4 |
AS |
$16.00 |
$198,288 |
D/D |
(12,393) |
1,701,276 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-21 |
4 |
OE |
$2.25 |
$27,884 |
D/D |
12,393 |
1,713,669 |
|
- |
|
| Harris Todd |
Chief Executive Officer |
• • – |
2023-03-15 |
4 |
A |
$6.58 |
$11,895 |
D/D |
1,808 |
1,701,276 |
|
- |
|
| Tada Hiroomi |
Chief Medical Officer |
• – – |
2023-03-15 |
4 |
A |
$6.58 |
$12,454 |
D/D |
1,893 |
83,130 |
|
- |
|
| Patel Piyush R. |
Chief Development Officer |
• – – |
2023-02-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
8,442 |
73,794 |
|
- |
|
| Davis Aaron I. |
|
• • • |
2023-02-10 |
4 |
S |
$13.40 |
$878,611 |
D/D |
(65,568) |
22,527 |
|
- |
|
| Davis Aaron I. |
|
• • • |
2023-02-09 |
4 |
S |
$13.10 |
$2,620,000 |
D/D |
(200,000) |
88,095 |
|
- |
|
| Patel Piyush R. |
Chief Development Officer |
• – – |
2022-10-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
56,276 |
82,236 |
|
- |
|
| Patel Piyush R. |
Chief Development Officer |
• – – |
2022-09-15 |
4 |
A |
$7.66 |
$7,965 |
D/D |
1,040 |
138,512 |
|
- |
|
| Tada Hiroomi |
Chief Medical Officer |
• – – |
2022-09-15 |
4 |
A |
$7.66 |
$4,687 |
D/D |
612 |
81,237 |
|
- |
|
| Van Den Boom Esther |
Chief Financial Officer |
• – – |
2022-09-15 |
4 |
A |
$7.66 |
$11,120 |
D/D |
1,452 |
121,897 |
|
- |
|
135 Records found
|
|
Page 4 of 6 |
|
|
